Episode Details
Back to Episodes
Hope in a Shot for Resistant Head Neck Cancer
Description
A breakthrough jab called amivantamab is delivering stunning results for head and neck cancer patients who’ve run out of options—shrinking tumors in over 40%, even causing complete disappearances in some. With mild side effects, this small injection blocks key cancer signals, offering renewed hope where chemo and immunotherapy failed. Patients report dramatic quality-of-life improvements, including reduced pain and restored ability to speak and eat. In a global trial of over 100 patients, median survival hit 1 year and 5 months—a major leap for this aggressive cancer. This game-changing treatment is now spotlighted at a top oncology conference.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/cff396f5121e7422